The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Kidney Cancer (Renal Cell Cancer).

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Ovarian Cancer.

On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...

Sacituzumab govitecan, currently indicated in triple-negative breast cancer (TNBC), is undergoing evaluation in NSCLC. In ...

Daiichi Sankyo has claimed approval in Japan, its home market, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab ...

CURE created a list of the top breast cancer stories of this year, including those focused on patient-reported outcomes and ...

The results of the TROPiCS-04 study compared Trodelvy (sacituzumab govitecan) to chemotherapy as second-line treatment for patients with locally advanced or metastatic UC previously treated with ...

INR:5297. bet365 founded The latest clinical progress of CRISPR/Cas9 gene editing therapy Everest Medicines' Phase 3 Clinical Trial Application for Sacituzumab Gov ...

rohit sharma ki wife Everest Medicines' Phase 3 Clinical Trial Application for Sacituzumab Govitecan Approved Pharmaceutical and Health Industry Weekly Report (September 23-September 27) [Two Sessions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

U.S. Surgeon General Calls for Cancer Warnings on Alcohol Dr. Vivek Murthy’s report cites studies linking alcoholic beverages to malignancies, including breast cancer. But to label them ...